Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00938756|
Recruitment Status : Unknown
Verified April 2010 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : July 14, 2009
Last Update Posted : April 7, 2010
RATIONALE: Studying samples of cerebrospinal fluid from patients with cancer or meningeal syndrome may help doctors identify biomarkers related to cancer.
PURPOSE: This clinical trial is studying cerebrospinal fluid samples in diagnosing carcinomatous meningitis in patients with cancer or meningeal syndrome.
|Condition or disease||Intervention/treatment||Phase|
|Brain and Central Nervous System Tumors Breast Cancer Metastatic Cancer||Other: diagnostic laboratory biomarker analysis Other: immunoenzyme technique Procedure: magnetic resonance imaging||Not Applicable|
- Evaluate the validity of determining CA 15-3 levels in the cerebrospinal fluid (CSF) using automated immuno-enzymatic methods.
- Determine the sensitivity and specificity of these assays in assessing CA 15-3 in CSF.
- Assess favorability of intrathecal production of CA 15-3.
- Determine threshold interpretations of CA 15-3 levels in CSF.
OUTLINE: This is a multicenter study.
Within 15 days of suspected meningeal involvement, blood and cerebrospinal fluid samples are collected. Samples are examined by immunoenzyme assays. Patients with suspected cases of carcinomatous meningitis undergo cerebrospinal MRI.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Masking:||None (Open Label)|
|Official Title:||Interest of the Dosage of CA 15-3 in CSF for Diagnosing Carcinomatous Meningitis in Breast Cancer|
|Study Start Date :||April 2008|
|Estimated Primary Completion Date :||May 2009|
- CA 15-3 levels in cerebrospinal fluid
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00938756
|Centre Oscar Lambret||Recruiting|
|Lille, France, 59020|
|Contact: Emilie Le Rhun 33-32-029-5959|
|Principal Investigator:||Emilie Le Rhun||Centre Oscar Lambret|